Breathe Well Live Well
|
FDA expands indication for asthma rescue inhaler to younger patients
Healio Teva Pharmaceuticals announced today that the FDA has expanded the indication for its ProAir, RespiClick inhalation powder to include patients with asthma aged 4 to 11 years, according to a press release. Teva Pharma (TEVA) Receives FDA Approval for ProAir RespiClick for Pediatric Asthma Patients Ages 4 to 11 FDA Expands Breath-Actuated Inhaler Use to Kids as Young as 4 |
View full post on asthma – Google News
|
FDA expands indication of BI inhaler to include maintenance treatment of asthma
FierceDrugDelivery The only inhaler that administers a slow-moving mist to help respiratory patients inhale the medication is now FDA-approved for the long-term maintenance treatment of asthma, in addition to its previous indication to treat COPD. The expanded indication … FDA Approves New Indication for Boehringer's Spiriva Respimat Landmark year for Boehringer Ingelheim's respiratory portfolio – new data for … ERS 2015: Landmark year for Boehringer Ingelheim's respiratory portfolio – new … |
View full post on asthma – Google News
European Pharmaceutical Review |
Spiriva Respimat (Tiotropium) Gets Asthma Indication in US
Medscape The US Food and Drug Administration (FDA) has approved the long-acting muscarinic antagonist tiotropium bromide (Spiriva Respimat, Boehringer Ingelheim) for long-term maintenance treatment of asthma in people aged 12 years and older, according to a … FDA approves Boehringer's asthma treatment FDA approves asthma treatment Spiriva Respimat |
View full post on asthma – Google News
|
Asthma Indication Sought for COPD Treatment
Pharmacy Times “There is a critical need for a new treatment option to provide benefits to, and improve outcomes for, patients with asthma,” said Klaus Dugi, chief medical officer for Boehringer Ingelheim, in a press release. “The FDA's acceptance of our application … |
View full post on asthma – Google News
|
COPD Tops Asthma as the Focus Indication for Next Generation Respiratory …
MarketWatch (press release) COPD has superseded asthma as the lead indication in the market race, most likely due to the FDA's new safety controls pertaining to limited use of all LABA-containing drugs in asthma as well as the unmet need for improved therapies for COPD," states … |
View full post on asthma – Google News